Regeneron Pharmaceuticals (REGN) Accumulated Expenses (2010 - 2026)

Regeneron Pharmaceuticals' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $2.7 billion for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 21.53% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $2.7 billion (up 21.53% YoY), while the FY2025 annual figure was $2.9 billion, up 13.82% from the prior year.
• Accumulated Expenses was $2.7 billion for Q1 2026 at Regeneron Pharmaceuticals, down from $2.9 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.0 billion in Q3 2025 to a low of $1.8 billion in Q3 2022.
• Historically, Accumulated Expenses has averaged $2.4 billion across 5 years, with a median of $2.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses decreased 12.84% in 2022, then jumped 47.22% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $2.1 billion in 2022, then climbed by 13.68% to $2.4 billion in 2023, then climbed by 7.18% to $2.5 billion in 2024, then advanced by 13.82% to $2.9 billion in 2025, then dropped by 5.28% to $2.7 billion in 2026.
• The last three Accumulated Expenses figures came in at $2.7 billion (Q1 2026), $2.9 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.